Fenfluramine · Fintepla
Small molecule
Also known as ZX008
Evidence outlook
Approved: Epilepsy (label: seizures of Dravet syndrome and Lennox-Gastaut syndrome, age 2 and older), Dravet Syndrome, Lennox-Gastaut Syndrome, Developmental and Epileptic Encephalopathies
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Rett Syndrome · Phase 3 · investigational in the US
Also approved (2)
- Use as an adjunctive therapy with other antiepileptic drugs to treat epileptic seizures in patients with Dravet syndrome who have not responded sufficiently to other antiepileptic drugs
- Treatment of seizures associated with Dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. Fintepla is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02682927 NCT02682927 · Dravet Syndrome, Seizure Disorder The trial was randomized, quadruple-blind, placebo-controlled, and included 262 participants, with convulsive seizure frequency as the primary clinical endpoint. The prespecified primary comparison favored fenfluramine, with statistically significant reductions versus placebo in both reported study groups. Registry: NCT02682927 | 3 | Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]) 2020-07-29 | Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966) | Reliable signal | link ↗ |
View 1 more trial
NCT03355209 NCT03355209 · Lennox-Gastaut Syndrome Part 1 was a randomized, double-blind, placebo-controlled comparison, and its primary endpoint, change in the frequency of seizures that cause drops, favoured the higher fenfluramine dose over placebo (median difference -19.9 percentage points, 95% CI -31.0 to -8.7, p=0.0008). The power calculation called for 75 patients per group, and each group in the main cohort enrolled at least 87. Registry: NCT03355209 | 3 | Part 1: Percent Change From Baseline in the Frequency of Seizures That Result in Drops (ESC-confirmed) in the Combined Titration and Maintenance Period (T+M) in the ZX008 0.8 mg/kg/Day Group Compared to the Placebo Group (From Baseline up to 14 weeks [Titration Period (2 weeks) + Maintenance Period (12 weeks)]); Part 2: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) (From Part 2 Baseline until end of the OLE Period (up to 72 months)); Part 2: Percentage of Participants With Serious TEAEs (From Part 2 Baseline until end of the OLE Period (up to 72 months)) 2024-05-23 | Percentage change from baseline in drop-seizure frequency, fenfluramine 0.7 mg/kg/day (n=87) vs placebo (n=87): median reduction 26.5 vs 7.6 percentage points; estimated median difference -19.9 percentage points (95% CI -31.0 to -8.7; P=.001). | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
This drug's own stage for Developmental and Epileptic Encephalopathies: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Fenfluramine (Fintepla): this drug | Approved | Small molecule | Serotonin 5-HT2 receptors | Reliable signal | NCT03355209: Percentage change from baseline in drop-seizure frequency, fenfluramine 0.7 mg/kg/day (n=87) vs placebo (n=87): median reduction 26.5 vs 7.6 percentage points; estimated median difference -19.9 percentage points (95% CI -31.0 to -8.7; P=.001). NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966) | |
| Cannabidiol (Epidiolex) | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | Reliable signal | NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2) | |
| Clobazam (Onfi) | Approved | Small molecule | GABA-A receptor | Reliable signal | NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100) | |
| Clobazam (Sympazan) | Approved | Small molecule | GABA-A receptor (benzodiazepine site) | not yet graded | No reviewed efficacy summary in this indication | |
| Ganaxolone | Approved | Small molecule | GABA-A receptor | Partial signal | NCT03572933: Median percentage change in 28-day major motor seizure frequency: ganaxolone -30.7% vs placebo -6.9% (p=0.0036); Hodges-Lehmann median difference -27.1% (95% CI -47.9 to -9.6), n=100 (Knight et al., Lancet Neurol 2022). | |
| Rufinamide | Approved | Small molecule | Voltage-gated sodium channel | not yet graded | No reviewed efficacy summary in this indication | |
| Stiripentol | Approved | Small molecule | GABA-A receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Vigabatrin (Sabril) | Approved | Small molecule | GABA transaminase (GABA-T) | not yet graded | No reviewed efficacy summary in this indication | |
| Vigabatrin (Vigafyde) | Approved | Small molecule | GABA transaminase (GABA-T) | not yet graded | No reviewed efficacy summary in this indication | |
| Relutrigine | Phase 3 | Small molecule | Voltage-gated sodium channel (persistent current) | not yet graded | No reviewed efficacy summary in this indication | |
| BMB-101 | Phase 2 | Small molecule | Serotonin 5-HT2C receptor (biased agonist) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Fintepla (Fenfluramine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (2)
2028 (1)
July 2028 (1)
What to watch
2029 (1)
February 2029 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent